Why the study?
Intravenous dantrolene is often prescribed for hypermetabolic syndromes other than malignant hyperthermia, but the extent of and indications for its use required clarification.
What are the indications, clinical characteristics, and outcomes associated with intravenous dantrolene use in critical care settings?
Population
304 inpatients receiving intravenous dantrolene in the U.S. Veterans Health Administration database
Comparison
Dantrolene vs no dantrolene in selected diagnoses
Design
Retrospective database survey
Authors
Loading...
Dantrolene use beyond MH warrants caution in critical care; leaves open questions on efficacy and safety pending prospective trials.
What are the indications, clinical characteristics, and outcomes associated with intravenous dantrolene use in critical care settings?
In the U.S. Veterans Health Administration, over 95% of intravenous dantrolene use is for off-label indications like neuroleptic malignant syndrome and sepsis, with uncertain efficacy and safety.
Caroff et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: